| Literature DB >> 35789835 |
Hong-Lin Liu1, Cai Cheng1, Ling-Zi Zuo1, Ming-Yue Yan1, Yan-Lin He1, Shi Huang1, Ming-Jing Ke2, Xiao-Liang Guo1, Yu Feng1, Hai-Feng Qian2, Ling-Ling Feng1.
Abstract
Harmful Microcystis blooms (HMBs) and microcystins (MCs) that are produced by Microcystis seriously threaten water ecosystems and human health. This study demonstrates an eco-friendly strategy for simultaneous removal of MCs and HMBs by adopting unique hyperoxic graphene oxides (HGOs) as carrier and pure microcystinase A (PMlrA) as connecting bridge to form stable HGOs@MlrA composite. After oxidation, HGOs yield inherent structural strain effects for boosting the immobilization of MlrA by material characterization and density functional theory calculations. HGO5 exhibits higher loading capacities for crude MlrA (1,559 mg·g-1) and pure MlrA (1,659 mg·g-1). Moreover, the performances of HGO5@MlrA composite, including the capability of removing MCs and HMBs, the ecological and human safety compared to MlrA or HGO5 treatment alone, have been studied. These results indicate that HGO5 can be used as a promising candidate material to effectively improve the application potential of MlrA in the simultaneous removal of MCs and HMBs.Entities:
Keywords: Applied microbiology; Materials chemistry; Materials science
Year: 2022 PMID: 35789835 PMCID: PMC9250033 DOI: 10.1016/j.isci.2022.104611
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Characterization of structural strain effects of HGOs (HGO1-HGO5)
(A) Schematic showing the overall process of HGO preparation.
(B) Scanning electron microscopy (SEM) images.
(C) Total oxygen content and functional group contents of GOs.
(D) C/O and ID/IG ratios.
(E) Average interlayer spacing.
(F) The loading capacities of HGOs for CMlrA in addition to HGO strain levels. HGO0 is the graphite powder used as the raw material.
Data are represented as mean ± SEM.
Figure 2Chemical characterization of HGO5@CMlrA
(A) Fourier transform infrared spectroscopy (FTIR) images.
(B) X-ray powder diffraction (XRD) images.
(C) Raman spectroscopy (RS) images.
(D) Energy dispersive X-ray spectroscopy (EDS) images.
Figure 3Preparation of HGO5@CMlrA and its assembly mechanism
(A and B) Schematics for HGO5@CMlrA and HGO0@CMlrA assembly, respectively.
(C and D) Atomic force microscopy (AFM) images of HGO5@CMlrA and HGO0@CMlrA, respectively.
(E and F) Density functional theory (DFT) calculations for HGO5@CMlrA and HGO0@CMlrA, respectively. Blue indicates negative potential and red indicates positive potentials.
Figure 4The effects of HGO5@CMlrA treatment on M. aeruginosa cells
(A) Cell morphology observations using scanning electron microscopy (SEM), transmission electron microscopy (TEM), and fluorescence confocal scanning electron microscopy (FCSEM).
(B) Chlorophyll a (Chl-a) contents.
(C and D) The maximum quantum yields of photosystem II (F/F); (D) The maximum relative electron transfer rates (rETRmax).
(E) Intercellular MC-LR (LRin) and extracellular MC-LR (LRex) contents.
(F) Culture pH at different days. BC indicates the control group.
Asterisks (∗, ∗∗, and ∗∗∗) represent statistically significant differences compared to controls (p < 0.05, p < 0.01, and p < 0.001, respectively; n = 3). Data are represented as mean ± SEM.
Figure 5Schematic illustrating intracellular and extracellular changes after treatment with HGO5@CMlrA compared with control group treatments (CMlrA or HGO5 alone) in M. aeruginosa cultures
The lengths and widths of the red lines represent positive correlations between the inhibition intensity of various treatments and the various indices.
Figure 6Optimization strategy of HGO5@CMlrA treatment that combines CMlrA with HGO5
(A) Schematic diagram showing the process of HGO5@CMlrA preparation and application. F-PMlrA indicates free PMlrA, I-PMlrA indicates PMlrA immobilized on HGOs, BPs indicate beneficial or harmless products other than PMlrA within the CMlrA, and HPs indicate harmful products within CMlrA.
(B) Effects of HGO5@CMBP composites on M. aeruginosa growth. Data are represented as mean ± SEM.
Figure 7Ecological safety of HGO5@CMlrA treatment evaluated with effects on bacterial communities
(A) Alpha diversity index values for bacterial communities.
(B) Principal coordinates analysis (PCoA) ordinations of variation in bacterial community composition across treatments.
(C) Bray-Curtis dissimilarities among treatment communities. Letters indicate statistically significant differences between different groups. Different letters in (C) represent significant differences (p < 0.05) between different treatments.
(D) Major bacterial genera of communities that exhibited relative abundances (RAs) > 1%.
(E) Major genera in the HGO5@CMlrA treatment group that exhibited statistically significant differences relative to other groups (up), in addition to genera in both the HGO5@CMlrA and CMlrA groups that exhibited significantly different abundances among the other two groups (down).
Asterisks (∗, ∗∗, and ∗∗∗) indicate statistically significant differences compared to controls (p < 0.05, p < 0.01, and p < 0.001, respectively). Data are represented as mean ± SEM.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| pMAL-c2X vector | New England Biolabs Inc. | Cat#E8000S |
| Institute of Hydrobiology, Chinese Academy of Sciences (Wuhan, China) | FACHB-905 | |
| Institute of Hydrobiology, Chinese Academy of Sciences (Wuhan, China) | FACHB-898 | |
| Institute of Hydrobiology, Chinese Academy of Sciences (Wuhan, China) | FACHB-1227 | |
| pMAL-c2X- | This paper | N/A |
| Graphite | Maclin Biochemical Technology Co., Ltd. (Shanghai, China) | 7782-42-5 |
| H2SO4 | Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China) | 7664-93-9 |
| NaNO3 | Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China) | 7631-99-4 |
| H2O2 | Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China) | 7722-84-1 |
| KMnO4 | Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China) | 7722-64-7 |
| CGOs | Suzhou Crystal Silicon Electronic Technology Co., Ltd. (Suzhou, China) | 1034343-98-0 |
| ZGO0 | Professor Heping Zeng of Sun Yat-Sen University | |
| FITC | Maclin Biochemical Technology Co., Ltd. (Shanghai, China) | 3326-32-7 |
| EDC | Aladdin industrial corporation (Shanghai, China) | 25952-53-8 |
| NHS | Aladdin Biochemical Technology Co., Ltd. (Shanghai, China) | 106627-54-7 |
| MES | Aladdin Biochemical Technology Co., Ltd. (Shanghai, China) | 4432-31-9 |
| MC-LR | Express Technology Co., Ltd. (Beijing, China) | 101043-37-2 |
| MC-RR | Express Technology Co., Ltd. (Beijing, China). | 111755-37-4 |
| MC-YR | Enzo Life Sciences, Inc. (Beijing, China) | 101064-48-6 |
| CCK-8 Cell Proliferation and Cytotoxicity Assay Kit | Solarbio Co, Ltd | CA1210 |
| LDH activity detection kit | Solarbio Co. Ltd | BC0680 |
| RNeasy Plus Mini Kit | Qiagen, China | Qiagen 74136 |
| Transcriptor First Strand cDNA Synthesis Kit | Roche | 04896866001 |
| LightCycler 480 SYBR Green1 Master | Roche | 04887352001 |
| LO2 (normal liver cell line) | ATCC | BJ-0432 |
| Huh7(liver cancer cell line) | ATCC | BJ-0271 |
| ACHN (renal cancer cell line) | ATCC | BJ-0172 |
| Primer for 16s (338F) 5′-ACTCC | N/A | |
| Primer for 16s (806R) 5′-GGACT | N/A | |
| Primer for 18s (528F) 5′-GCGG | N/A | |
| Primer for 18s (706R) 5′-AATC | N/A | |
| Primer for | Peng et al. 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Peng et al., 2017 | N/A |
| Primer for | Gao et al., 2013 | N/A |
| Primer for | Gao et al., 2013 | N/A |
| Primer for | N/A | |
| Primer for | N/A | |
| Gene Bank | AB468058.1 | |
| Plasmid: pMAL-c2X- | This paper | N/A |
| QIIME2 software | Rideout et al., 2019 | |
| Multiwfn (A Multifunctional Wavefunction Analyzer) | Lu et al., 2012 | |
| Visual Molecular Dynamics (VMD) software program | ||